🇺🇸 brompheniramine + phenylephrine in United States
21 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 21
Most-reported reactions
- Dehydration — 3 reports (14.29%)
- Diarrhoea — 3 reports (14.29%)
- Acute Kidney Injury — 2 reports (9.52%)
- Clostridium Difficile Infection — 2 reports (9.52%)
- Hypovolaemia — 2 reports (9.52%)
- Mucosal Inflammation — 2 reports (9.52%)
- Muscle Spasms — 2 reports (9.52%)
- Palmar-Plantar Erythrodysaesthesia Syndrome — 2 reports (9.52%)
- Palpitations — 2 reports (9.52%)
- Accidental Drug Intake By Child — 1 report (4.76%)
Other Allergy/Immunology approved in United States
Frequently asked questions
Is brompheniramine + phenylephrine approved in United States?
brompheniramine + phenylephrine does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for brompheniramine + phenylephrine in United States?
Ache Laboratorios Farmaceuticos S.A. is the originator. The local marketing authorisation holder may differ — check the official source linked above.